 | This article needs additional citations for verification .(April 2017) |
Cannabis in France is illegal for personal use, but remains one of the most popular illegal drugs. Limited types of cannabis-derived products are permitted for medical uses.
| | This article needs additional citations for verification .(April 2017) |
Cannabis in France is illegal for personal use, but remains one of the most popular illegal drugs. Limited types of cannabis-derived products are permitted for medical uses.
During Napoléon Bonaparte's invasion of Egypt in 1798, alcohol was not available as Egypt was an Islamic country. [1] In place of alcohol, Bonaparte's troops resorted to trying hashish, which they found to their liking. [1] As a result of the conspicuous consumption of hashish by the troops, the smoking of hashish and consumption of drinks containing it was banned in October 1800, although the troops mostly ignored the order. [1] Subsequently, beverages containing hashish were banned in Egyptian cafes; cafes that sold them were shut down and "boarded up", and their proprietors were jailed. [1] During this time, hashish imported from other countries was destroyed by burning. [1] Upon the end of the occupation in 1801, French troops brought supplies of hashish with them back to France. [1]
In the mid-1800s, following travel and studies in Asia, French psychiatrist Jacques-Joseph Moreau studied hashish extensively and produced the 1845 work Du Hachisch et de l'aliénation mentale (Hashish and Mental Illness). [2]
In the 1800s, hashish was embraced in some European literary circles. Most famously, the Club des Hashischins was a Parisian club dedicated to the consumption of hashish and other drugs; its members included authors Théophile Gautier, Moreau de Tours, Victor Hugo, Alexandre Dumas, Charles Baudelaire and Honoré de Balzac. [3] Baudelaire later wrote the 1860 book Les paradis artificiels about the state of being under the influence of opium and hashish.
In France, possession and use of cannabis fall under criminal law and the Loi du 31 décembre 1970, regarding health measures against drug abuse and suppression of drug trafficking.
In French law, free speech is not permitted in relation to narcotic drugs, as Article L-3421-4 (formerly L 630 [4] ) of the Public Health code states that:
Provocation to commit the offence provided for in Article L. 3421-1 or one of the offences provided for in Articles 222-34 to 222 3421-1 or one of the offences provided for in Articles 222-34 to 222-39 of the Criminal Code [i.e. any drug-related infraction], even if such provocation has not been followed up, or the fact of presenting these offences in a favorable light, shall be punishable by five years’ imprisonment and a fine of 75,000 euros [5]
The vague and broad terms highlighted in the quote above have given rise to criticism [6] and controversial legal action against cannabis activists, book editors, and online content creators. [7]
France is a signatory to the 1961 Single Convention on narcotic drugs, and had banned cannabis as a medical treatment already in 1953. Since then, the importation, sale, transport and production of cannabis and cannabinoids has been illegal in France. In 1999, the Agence Française de Sécurité Sanitaire des Produits de Santé made temporary use authorisations for health products otherwise not permitted on the French market. In 1991 a court rejected the demands of the NGO Mouvement pour la Légalisation Contrôlée concerning the importation of cannabis to supply 10 patients suffering terminal illness, arguing that such was incompatible with France's adherence to the 1961 UN Single Convention on Narcotic Drugs, and MLC's inability to scientifically control and administer medical cannabis.
As of 8 June 2013, cannabis derivatives can be used in France for the manufacture of medicinal products. The products can only be obtained with a prescription and will only be prescribed when all other medications have failed to effectively relieve suffering. The amended legislation decriminalises "the production, transport, export, possession, offering, acquisition or use of speciality pharmaceutials that contains one of these (cannabis-derivative) substances", while all cannabis products must be approved by the National Medical Safety Agency (Agence nationale de sécurité du médicament – ANSM). A Pharmacists' Union spokesperson explained to the media that the change will make it more straightforward to conduct research into cannabinoids. [8]
In September 2018, the french National Agency for Drug Safety (ANSM) started an experimentation on therapeutic cannabis. They created a scientific committee to evaluate a new public policy and distribution network for specific diseases. [9] This experiment will gather 3,000 patients and provide dried flowers and oils for people going under epilepsy, neuropathic pain or to treat side effects of chemotherapy. [10] The first test should start in September 2020 and will go on for two years. [11]
Because of the coronavirus pandemic, the ANSM informed that the experimentation will be delayed to January 2021. [12]
On 25 May 2017, the Minister of the Interior indicated his intention to implement reforms, promised by President Emmanuel Macron during his campaign, to substitute citations rather than arrest and trial for use and possession of cannabis. [13] On 23 November 2018 the penalty for possession of cannabis (and other illegal drugs) was reduced to a 200 euro fine, following a 28–14 vote by the National Assembly. [14] [15] On 1 September 2020, the French Government introduced a 200€ fine for cannabis consumption instead of being taken into custody. This measure will also be applied for cocaine detention. [16] Macron has ruled out legalising cannabis while he is in office and legalisation is also opposed by current government health minister Agnès Buzyn and Interior Minister Gérald Darmanin. [17]
Those that support the legalisation of cannabis in France include Julien Bayou, Benoît Hamon, Yannick Jadot, Jean-Luc Mélenchon, Pierre Person and Aurélien Taché. [18] [19] [20] [21] [22] In 2019, the French Conseil d'Analyse Économique published a report that recommended legalising cannabis for recreational use in France. [23]
In 2012, 13.4 million French people between age 15 and 64 had tried cannabis, and 1.2 million people in Metropolitan France considered themselves regular users. [24] France ranks fourth in the European Union in terms of monthly consumption (following the Czech Republic, Spain, and Italy) and second only to Denmark in terms of persons who have ever used cannabis. [25]
In 2015, the European Monitoring Centre for Drugs and Drug Addiction published a new report on drugs, saying that the French people were still the biggest cannabis consumers, especially in the 15–34 segment. The report is also affirming that the product quality is increasing, due to competition and technical innovation. [26]
A poll conducted by CSA in November 2013 indicated that, 55% of French people were opposed to the decriminalisation of cannabis, while 44% said that the prohibition on cannabis is an abridgment of individual liberty. [27]
In June 2018, an IFOP poll for Terra Nova and Echo Citoyen found that 51% were in favour of a regulated market in cannabis, and 40% were opposed. [28]
At the end of 2018, a poll by the French Observatory of Drugs and Addiction, a government body, found "nearly one in two" were favourable to legalisation with 54% opposed, while more than 9 in 10 were in favour of legalising medical cannabis. [29]
The legality of cannabis for medical and recreational use varies by country, in terms of its possession, distribution, and cultivation, and how it can be consumed and what medical conditions it can be used for. These policies in most countries are regulated by three United Nations treaties: the 1961 Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, and the 1988 Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. Since its descheduling in 2020, cannabis is classified as a Schedule I drug under the Single Convention treaty, meaning that signatories can allow medical use but that it is considered to be an addictive drug with a serious risk of abuse.
The Institut de veille sanitaire was a French public establishment of the Health minister. It was merged in 2016 with other health agencies into the Agence nationale de santé publique .
Pholcodine is an opioid cough suppressant (antitussive). It helps suppress unproductive coughs and also has a mild sedative effect, but has little or no analgesic effects. It is also known as morpholinylethylmorphine and homocodeine.
Cannabis in Switzerland is illegal, though minor possession was decriminalised to a fine in 2012. Several cantons began to allow adults to cultivate and use cannabis in 2012, but this was struck down by federal courts. In 2016, four cities stated they were looking into establishing pilot cannabis clubs. The number of cannabis users in Switzerland is estimated to be around 500,000 among a population of 8 million.
Agence nationale de sécurité du médicament et des produits de santé (ANSM) superseded the tasks and duties of Agence française de sécurité sanitaire des produits de santé (AFSSAPS) on 1 May 2012. It is responsible for assessing the benefits and risks associated with the use of drugs and other medical products throughout their life-cycle. ANSM assesses the safety, efficacy and quality of these products and must balance patient safety with access to novel therapies.
Cannabis had been illegal in Morocco since the nation's independence in 1956, reaffirmed by a total ban on drugs in 1974, but was partially tolerated in the country. Cannabis has been cultivated in Morocco for centuries and the country is currently among the world's top producers of hashish. As of 2016, Morocco was the world's top supplier of cannabis. On May 26, 2021, the Moroccan parliament voted to legalize the use of cannabis for medical, as well as cosmetic and industrial purposes.
BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. It interacts with the human endocannabinoid system. The drug was in development for the treatment of a range of different medical conditions from anxiety disorder to Parkinson's disease, also for the treatment of chronic pain of multiple sclerosis, cancer, hypertension or the treatment of obesity. A clinical trial with this drug was underway in Rennes, France, in January 2016, in which serious adverse events occurred affecting five participants, including the death of one man. The underlying mechanism that caused the acute neurotoxicity of this molecule remains unknown.
Cannabis in Spain is decriminalized for personal cultivation and use, and other purposes other than sale or trade. It's illegal for trade or commercial purposes. Using the legal grey areas in Spanish legislation, cannabis clubs are a popular way for enthusiasts to obtain and use cannabis as a technically-legal private collective. In private places, consumption and possession of reasonable amounts is legal.
Cannabis is illegal for cultivation, trade and personal use in Lebanon. Nevertheless, large amounts of cannabis are grown illegally within the country, especially in the Bekka Valley, and consumed for personal use in private.
Cannabis in Luxembourg is legal for recreational and medical use for adults under specific circumstances. A bill was passed in the country's parliament June 2023 to legalise the following for adults in Luxembourg: recreational possession, home-use of cannabis, and growing up to four cannabis plants per household. The law took effect on 21 July 2023.
The list includes and details significant events that occurred in the global history of national-level implementations of, or changes made to, laws surrounding the use, sale, or production of the psychoactive drug cannabis.
Delphine Bagarry is a French emergency physician and politician who was the National Assembly deputy for Alpes-de-Haute-Provence's 1st constituency from 2017 to 2022.
Cécile Rilhac is a French politician of La République En Marche! (LREM) who has been serving as a member of the French National Assembly since 18 June 2017, representing the department of Val-d'Oise.
Jérôme Salomon is a French infectious diseases physician and high-ranking civil servant. He is the French Directeur général de la Santé since 8 January 2018. He became known in France since the COVID-19 pandemic.
Sandrine Rousseau is a French economist and politician who has represented the 9th constituency of Paris in the National Assembly since 2022. A member of Europe Ecology – The Greens (EELV), she has been widely seen as a figurehead of France's MeToo movement against sexual violence; she describes herself as an ecofeminist.
Germaine Cousin-Zermatten, born in Switzerland on 22 April 1925 in Saint-Martin in the canton of Valais, is a Swiss herbalist and author who—following personal research aimed to compile an ancestral knowledge only transmitted orally—has written several books devoted to the phytotherapeutic properties of medicinal plants located in the Val d’Hérens region.
Germaine Benoit was a French chemical engineer, pharmacologist and biologist, best known for her contributions to the study of sympathomimetic drugs.
Cannabis Sans Frontières is a Paris-based organization advocating for cannabis and drug policy reform. Founded in 2005 by Farid Ghehiouèche and Michel Sitbon, the organization aims to destigmatize cannabis usage and influence legislative change both in France and Europe. Known for its multifaceted approach to advocacy, Cannabis Sans Frontières combines political engagement, public education, and cultural impact to push for more progressive drug policies. With a focus on human rights and harm reduction, the organization has gained visibility through its various campaigns, participation in elections, and frequent media appearances.
Hexahydrocannabiphorol is a semi-synthetic cannabinoid derivative which has been marketed since around 2021. It is believed to be made from the hydrogenation of tetrahydrocannabiphorol (THCP). THCP is only reported as a trace component of cannabis in 2019. HHCP was studied by Roger Adams as early as 1952.
Nayla Chidiac is a French Lebanese author, essayist and poetes. She nominated Legion of Honour in 2017.
{{cite web}}: CS1 maint: numeric names: authors list (link){{cite web}}: CS1 maint: numeric names: authors list (link){{cite web}}: CS1 maint: numeric names: authors list (link)